Evaluation of role of angiotensin III and aminopeptidases in prostate cancer cells

Prostate

Volumn 68, Issue 15, 2008, Pages 1666-1673

  Teranishi, Jun Ichi ^a   Ishiguro, Hitoshi ^b   Hoshino, Koji ^b   Noguchi, Kazumi ^a   Kubota, Yoshinobu ^b   Uemura, Hiroji ^b,c  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^b YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Aminopeptidase; Angiotensin III; Prostate cancer

Indexed keywords

ANGIOTENSIN III; DEXAMETHASONE; ESTRADIOL; GLUTAMYL AMINOPEPTIDASE; MESSENGER RNA; MICROSOMAL AMINOPEPTIDASE; MITOGEN ACTIVATED PROTEIN KINASE; OLMESARTAN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EVALUATION; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; DRUG EFFECT; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROSTATE TUMOR; TUMOR CELL LINE;

ANGIOTENSIN III; ANTIGENS, CD13; ANTINEOPLASTIC AGENTS, HORMONAL; CELL LINE, TUMOR; CELL PROLIFERATION; DEXAMETHASONE; ESTRADIOL; GLUTAMYL AMINOPEPTIDASE; HUMANS; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RNA, MESSENGER;

EID: 55249097976     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20835     Document Type: Article

References (32)

1. Uemura H, Nakaigawa N, Ishiguro H, Kubota Y. Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer. Curr Cancer Drug Targets 2005;5(5):307-323.
2. Heffelfinger SC. The renin angiotensin system in the regulation of angiogenesis. Curr Pharm Des 2007;13(12):1215-1229.
3. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JW. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998;352(9123):179-184.
4. Uemura H, Ishiguro H, Nakaigawa N, Nagashima Y, Miyoshi Y, Fujinami K, Sakaguchi A, Kubota Y. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: A possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2003;2(11):1139-1147.
5. O'Mahony OA, Djahanbahkch O, Mahmood T, Puddefoot JR, Vinson GP. Angiotensin II in human seminal fluid. Hum Reprod 2000;15(6):1345-1349.
6. Fraser LR, Pondel MD, Vinson GP. Calcitonin, angiotensin II and FPP significantly modulate mouse sperm function. Mol Hum Reprod 2001;7(3):245-253.
7. Fraser LR, Osiguwa OO. Human sperm responses to calcitonin, angiotensin II and fertilization-promoting peptide in prepared semen samples from normal donors and infertility patients. Hum Reprod 2004;19(3):596-606.
8. Kenny AJ, O'Hare MJ, Gusterson BA. Cell-surface peptidases as modulators of growth and differentiation. Lancet 1989;2(8666):785-787.
9. King KA, Hua J, Torday JS, Drazen JM, Graham SA, Shipp MA, Sunday ME. CD10/neutral endopeptidase 24.11 regulates fetal lung growth and maturation in utero by potentiating endogenous bombesin-like peptides. J Clin Invest 1993;91(5):1969-1973.
10. Shipp MA, Tarr GE, Chen CY, Switzer SN, Hersh LB, Stein H, Sunday ME, Reinherz EL. CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc Natl Acad Sci USA 1991;88(23):10662-10666.
11. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: Current status and future prospects. Prostate 2004;61(4):332-353.
12. Cunha GR. Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. Cancer 1994;74(3 Suppl):1030-1044.
13. Miyoshi Y, Uemura H, Fujinami K, Mikata K, Harada M, Kitamura H, Koizumi Y, Kubota Y. Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients. Prostate 2000;43(3):225-232.
14. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61(9):3550-3555.
15. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332(21):1393-1398.
16. Vauquelin G, Michotte Y, Smolders I, Sarre S, Ebinger G, Dupont A, Vanderheyden P. Cellular targets for angiotensin II fragments: Pharmacological and molecular evidence. J Renin Angiotensin Aldosterone Syst 2002;3(4):195-204.
17. Uemura H, Hasumi H, Ishiguro H, Teranishi J, Miyoshi Y, Kubota Y. Renin-angiotensin system is an important factor in hormone refractory prostate cancer. Prostate 2006;66(8):822-830.
18. Deshayes F, Nahmias C. Angiotensin receptors: A new role in cancer? Trends Endocrinol Metab 2005;16(7):293-299.
19. Kambayashi Y, Bardhan S, Takahashi K, Tsuzuki S, Inui H, Hamakubo T, Inagami T. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem 1993;268(33):24543- 24546.
20. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 1993;268(33):24539-24542.
21. Uemura H, Ishiguro H, Nagashima Y, Sasaki T, Nakaigawa N, Hasumi H, Kato S, Kubota Y. Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells. Mol Cancer Ther 2005;4(11):1699-1709.
22. Harding JW, Felix D. Angiotensin-sensitive neurons in the rat paraventricular nucleus: Relative potencies of angiotensin II and angiotensin III. Brain Res 1987;410(1):130-134.
23. Katsumata Y, Nomura S, Ino K, Iwanaga K, Kurosawa N, Ito T, Okada M, Tsujimoto M, Kikkawa F, Mizutani S. Progesterone stimulates the expression of aminopeptidase A/angiotensinase in human choriocarcinoma cells. Placenta 2001;22(10):831-836.
24. Marchio S, Lahdenranta J, Schlingemann RO, Valdembri D, Wesseling P, Arap MA, Hajitou A, Ozawa MG, Trepel M, Giordano RJ, Nanus DM, Dijkman HB, Oosterwijk E, Sidman RL, Cooper MD, Bussolino F, Pasqualini R, Arap W. Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell 2004;5(2):151-162.
25. Fujimura H, Ino K, Nagasaka T, Nakashima N, Nakazato H, Kikkawa F, Mizutani S. Aminopeptidase A expression in cervical neoplasia and its relationship to neoplastic transformation and progression. Oncology 2000;58(4):342-352.
26. Quaroni A, Nichols BL, Quaroni E, Hurst K, Herrera L, Weiser MM, Hamilton SR. Expression and different polarity of aminopeptidase N in normal human colonic mucosa and colonic tumors. Int J Cancer 1992;51(3):404-411.
27. Dixon J, Kaklamanis L, Turley H, Hickson ID, Leek RD, Harris AL, Gatter KC. Expression of aminopeptidase-n (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin. J Clin Pathol 1994;47(1):43-47.
28. Bogenrieder T, Finstad CL, Freeman RH, Papandreou CN, Scher HI, Albino AP, Reuter VE, Nanus DM. Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue. Prostate 1997;33(4):225-232.
29. Ishii K, Usui S, Yamamoto H, Sugimura Y, Tatematsu M, Hirano K. Decreases of metallothionein and aminopeptidase N in renal cancer tissues. J Biochem 2001;129(2):253-258.
30. Varona A, Blanco L, Lopez JI, Gil J, Agirregoitia E, Irazusta J, Larrinaga G. Altered levels of acid, basic, and neutral peptidase activity and expression in human clear cell renal cell carcinoma. Am J Physiol Renal Physiol 2007;292(2):F780-F788.
31. Menrad A, Speicher D, Wacker J, Herlyn M. Biochemical and functional characterization of aminopeptidase N expressed by human melanoma cells. Cancer Res 1993;53(6):1450-1455.
32. Saiki I, Fujii H, Yoneda J, Abe F, Nakajima M, Tsuruo T, Azuma I. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int J Cancer 1993;54(1):137-143.